Savient Pharmaceuticals skids on no end to strategic business development
Shares of Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) are under pressure after the biopharmaceutical company said that it continues to evaluate strategic business development options for its product, pegloticase, but that nothing had materialized. The firm further stated that nothing may come to fruition period.
Shares slipped 11%, or $2 to $16.72 in late morning trading. For detailed price information and news stories on Savient Pharmaceuticals, click SVNT.
